Clin2
NCT05532813Possibly a fitRecruiting

Metformin for adult myotonic dystrophy type 1 muscle weakness

Steinert's DiseaseMyotonic Dystrophy 1Metformin

Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.

This Phase 3 trial tests whether metformin can improve symptoms and safety in adults with genetically confirmed myotonic dystrophy type 1 (DM1). It may help reduce muscle problems, but you must meet specific walking, breathing, heart, and kidney requirements.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
142 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You have DM1 confirmed by genetic testing
  • You are age 18 to 70 (men or women)
  • You can still walk with at most stick/cane-type help
  • Your mobility score (MIRS) is 3 or 4
  • If you can have a pregnancy, you can use effective birth control during the study
  • You can provide consent and you are enrolled through your social security system

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06101940Enrolling by invitation
Chinese study tracking myotonic dystrophy type 1 outcomes

This study follows people with myotonic dystrophy type 1 (DM1) over time to learn more about how the disease progresses. It collects health information and samples to help improve care.

Beijing, Beijing Municipality
NCT06300307Recruiting· Phase 1/Phase 2
Study of ATX-01 for Myotonic Dystrophy Type 1

This trial tests an experimental drug called ATX-01 for people with myotonic dystrophy type 1 (DM1), a condition that causes muscle weakness and stiffness. The study aims to see if ATX-01 can help reduce symptoms like muscle stiffness (myotonia) and improve daily function.

Los Angeles, California
NCT06138743Recruiting· Phase 1/Phase 2
Investigational treatment for adult-onset myotonic dystrophy type 1

This trial is testing a new drug called SRP-1003 for people with myotonic dystrophy type 1 (DM1) who developed symptoms after age 12. The goal is to see if it can reduce muscle problems like myotonia (difficulty relaxing muscles) and improve daily function.

Liverpool, New South Wales
NCT03981575Recruiting
Biomarker and health marker study in myotonic dystrophy type 1

This study measures physical and lab “health markers” in people with myotonic dystrophy type 1 (DM1) to better understand how the disease changes over time. Some participants may also have a muscle biopsy to study tissue differences.

La Jolla, California
NCT07700225Recruiting
Long-term study of myotonic dystrophy type 1

This study is a long-term follow-up for people with myotonic dystrophy type 1. It aims to find better ways to measure how the disease progresses, which could help develop future treatments.

Richmond, Virginia
NCT06185179Recruiting· Early Phase 1
Metformin for muscle recovery in older adults

This study tests whether a common diabetes medicine called metformin can help your muscles recover faster after a minor injury. You may qualify if you are 60 or older, generally healthy, and not taking certain medicines.

Salt Lake City, Utah

Hear when a new Myotonic Dystrophy 1 trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.